Suppr超能文献

嵌合抗原受体T细胞(CAR-T)疗法:从癌症到自身免疫性疾病的发展、挑战及应用拓展

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity.

作者信息

Kong Yaojie, Li Jingyao, Zhao Xueyao, Wu Yanwei, Chen Liang

机构信息

School of Medicine, Shanghai University, Shanghai, China.

出版信息

Front Immunol. 2025 Jan 9;15:1519671. doi: 10.3389/fimmu.2024.1519671. eCollection 2024.

Abstract

Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging. This review summarized the development of CAR-T technologies, emphasized the challenges and solutions in CAR-T cell therapy for solid tumors. Also, key innovations were discussed including specialized CAR-T, combination therapies and the novel use of CAR-Treg, CAR-NK and CAR-M cells. Besides, CAR-based cell therapy have extended its reach beyond oncology to autoimmune disorders. We reviewed preclinical experiments and clinical trials involving CAR-T, Car-Treg and CAAR-T cell therapies in various autoimmune diseases. By highlighting these cutting-edge developments, this review underscores the transformative potential of CAR technologies in clinical practice.

摘要

嵌合抗原受体(CAR)-T细胞疗法已迅速成为癌症治疗中的一种开创性方法,尤其是在血液系统恶性肿瘤治疗方面。然而,CAR-T细胞疗法在实体瘤中的应用仍然具有挑战性。本综述总结了CAR-T技术的发展,强调了CAR-T细胞疗法在实体瘤治疗中的挑战及解决方案。此外,还讨论了关键创新,包括特殊的CAR-T、联合疗法以及CAR-Treg、CAR-NK和CAR-M细胞的新用途。此外,基于CAR的细胞疗法已将其应用范围从肿瘤学扩展到自身免疫性疾病。我们回顾了涉及CAR-T、Car-Treg和CAAR-T细胞疗法在各种自身免疫性疾病中的临床前实验和临床试验。通过突出这些前沿进展,本综述强调了CAR技术在临床实践中的变革潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e00e/11754230/c4775a6bdb59/fimmu-15-1519671-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验